Articles récents
- Op2Lysis is a silver sponsor of the WICH 2023 conference and will have the opportunity to give two oral presentations to an expert audience in cerebral haemorrhage
- New support from Bpifrance for €1.5M, covering the GMP production of the Drug Substance OptPA, has been obtained
- Retrospective – 2022 in a nutshell
- The EIC Accelerator grant agreement has been signed by the European Innovation Council and provides €2.5M support to the O2L-001 development programme
- Orphan drug designation granted to OptPA for the treatment of non-traumatic spontaneous intracerebral hemorrhage by the European Commission